About sutro biopharma inc - STRO
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
STRO At a Glance
Sutro Biopharma, Inc.
111 Oyster Point Boulevard
South San Francisco, California 94080
| Phone | 1-650-881-6500 | Revenue | 102.48M | |
| Industry | Pharmaceuticals: Major | Net Income | -191,086,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 65.182% | |
| Fiscal Year-end | 12 / 2026 | Employees | 137 | |
| View SEC Filings |
STRO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.959 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.968 |
| Enterprise Value to Sales | 1.874 |
| Total Debt to Enterprise Value | 1.224 |
STRO Efficiency
| Revenue/Employee | 748,058.394 |
| Income Per Employee | -1,394,788.321 |
| Receivables Turnover | 25.769 |
| Total Asset Turnover | 0.365 |
STRO Liquidity
| Current Ratio | 2.009 |
| Quick Ratio | 2.009 |
| Cash Ratio | 1.882 |
STRO Profitability
| Gross Margin | 92.854 |
| Operating Margin | -102.408 |
| Pretax Margin | -186.545 |
| Net Margin | -186.454 |
| Return on Assets | -68.119 |
| Return on Equity | N/A |
| Return on Total Capital | -185.957 |
| Return on Invested Capital | -113.722 |
STRO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 228.897 |
| Total Debt to Total Assets | 135.31 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 221.323 |